Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
DRMA
vs
S&P 500
DRMA
S&P 500
Over the past 12 months, DRMA has underperformed S&P 500, delivering a return of -78% compared to S&P 500's +13% growth.
Stocks Performance
DRMA vs S&P 500
Performance Gap
DRMA vs S&P 500
Create a free account · No card needed
Performance By Year
DRMA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Dermata Therapeutics Inc
Glance View
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The company went IPO on 2021-08-13. The firm is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
